Open Outbreak

West Nile virus

Also known as: WNV, West Nile fever

West Nile virus is a mosquito-borne virus that circulates mainly between birds and mosquitoes. People and horses can become infected, but they do not normally pass the virus back to mosquitoes. Most human infections follow a bite from an infected mosquito. Rare infections have also occurred through blood transfusions and organ transplants. WHO reports that about 80% of infected people have no symptoms. About 20% develop a fever illness, while approximately 1 in 150 develops serious disease affecting the brain or nervous system. Older adults and people with weakened immune systems face a higher risk of severe illness. The virus occurs across several continents, including Africa, Europe and the Americas. The WHO sources retrieved describe no available human vaccine; vaccines exist for horses. Treatment for severe illness is supportive, including hospital care and breathing support when needed. Surveillance of mosquitoes, birds, horses and human illness helps identify changes in local risk. The sources retrieved do not establish the current situation in Occitanie, France.

Key facts

TransmissionMainly bites from infected mosquitoes, especially Culex mosquitoes. Rare transmission through blood transfusions, organ transplants, breast milk and pregnancy has been reported. No documented spread through casual human contact in the retrieved WHO sources.
IncubationUsually 3–14 days, according to WHO.
Case fatalityunknown; the retrieved sources describe potentially fatal disease but do not provide a case-fatality estimate or a treated-versus-untreated comparison.
Reproduction numberunknown; no numerical R0 or secondary attack rate was established in the retrieved sources.
VaccineNo human vaccine is available according to the retrieved WHO sources, including its 2024 notice. Horse vaccines are available. A 2026 status update was not retrieved.
TreatmentSupportive care for severe disease, often including hospitalization, intravenous fluids, respiratory support and prevention of secondary infections.
ReservoirBirds; the virus is maintained in a bird–mosquito cycle. Humans and horses are dead-end hosts.
Endemic regionsWidely present in Africa, Europe, the Middle East, West Asia and North America; WHO also describes establishment in the Americas from Canada to Venezuela and spread through the Caribbean.

Transmission

West Nile virus usually reaches people through the bite of an infected mosquito. Mosquitoes acquire it while feeding on infected birds, then can pass it on during later bites. Culex mosquitoes are the main carriers. Birds maintain the natural transmission cycle. Humans and horses are described as “dead-end hosts”: they can become ill but do not pass the infection back to mosquitoes. WHO reports rare transmission through blood transfusions, organ transplants, breast milk and pregnancy. It also describes transmission through contact with infected animal blood or tissues. Casual contact between people has not been documented as a route of spread in the retrieved WHO sources. No numerical reproduction number was provided.

Symptoms and severity

WHO estimates that around 80% of infected people have no symptoms. About 20% develop West Nile fever, which can cause fever, headache, tiredness, body aches, nausea or vomiting. Some people also develop a rash or swollen glands. Symptoms usually begin 3–14 days after infection. Approximately 1 in 150 infected people develops severe disease involving the brain or nervous system. Warning signs include high fever, neck stiffness, confusion, seizures, muscle weakness and paralysis. Severe illness can occur at any age, but people over 50 and those with weakened immune systems are at higher risk. The retrieved sources say the disease can be fatal, but do not provide a case-fatality percentage.

Treatment and vaccines

WHO describes treatment for severe West Nile disease as supportive care: keeping the person hydrated, supporting breathing and preventing secondary infections. People with disease affecting the brain or nervous system may need hospital care. The retrieved sources do not establish a specific antiviral treatment or quantify how treatment changes the risk of death. WHO’s fact sheet and its 2024 Barbados notice state that no vaccine is available for humans. Its Portugal notice describes vaccines available for horses; these are not human vaccines. No 2026 vaccine-status update was retrieved. Because the early symptoms overlap with other illnesses, diagnosis may require laboratory testing rather than symptoms alone.

Where it occurs

WHO describes West Nile virus as commonly found in Africa, Europe, the Middle East, North America and West Asia. Its fact sheet also describes establishment across the Americas, from Canada to Venezuela. Migratory birds can carry the virus between regions, while local mosquitoes sustain transmission. The 2024 Barbados notice describes spread through the Caribbean and the possibility of undetected circulation in birds and horses. Presence in a country does not mean every locality has the same risk. Animal and mosquito surveillance help identify local circulation. Open Outbreak lists Occitanie, France, as a monitoring record, but the retrieved sources do not verify its current case numbers or local transmission status.

Recent history

The supplied site metadata lists zero archived events, but the history tool returned five entries: United States and Canada notices in 2002, Brazil in 2014, Portugal in 2015 and Barbados in 2024. This discrepancy means the archive count needs reconciliation; neither count represents the worldwide number of outbreaks. The WHO search also returned additional notices. WHO reported Brazil’s first detected human case on 2014-12-15. Its notice dated 2024-10-03 described Barbados’s first detected human case, notified on 2024-09-13. WHO assessed the Barbados risk as low at that time, with one recorded human case and response measures underway. That assessment is historical, not a verified assessment for 2026-11-22.

What to watch

Important warning signals include locally acquired infections in new regions, increasing severe human illness, and evidence of infection in mosquitoes, birds or horses. WHO notes that animal outbreaks can precede human cases, making animal surveillance useful for early warning. Confirmed transmission through donated blood or organs would also warrant attention. Evidence of routine person-to-person spread would be a major change from the pattern described in the retrieved sources, which report no casual-contact transmission. For prevention and care, watch for verified changes in human vaccine availability or effective treatment. The retrieved evidence establishes neither a treatment-resistance trend nor a human vaccine supply programme. Current local surveillance is needed before drawing conclusions about Occitanie.

Related outbreaks

Updated